(Press-News.org) The topics of human-level artificial general intelligence (AGI) and artificial superintelligence (ASI) have captivated researchers for decades. Interest has surged with the rapid progress and deployment of large language models (LLMs), which now handle tasks such as coding, scientific explanation, creative writing, and multimodal reasoning. “Solve AI and it will solve everything” remains a popular, if contested, credo—driving large-scale investment, shaping public narratives, and motivating optimism about transformative advances.
Applying this vision to the healthcare and pharmaceutical industries, Insilico Medicine—a leading generative AI-driven drug discovery company — defines the pharmaceutical superintelligence (PSI) as the next step of AI-driven drug discovery, it showcases a fully-autonomous platform capable of discovering and designing a perfect small molecule or a biologic drug, together with the biomarker for patient selection, producing a significant disease-modifying or curative response for any disease without failure and without the need for further human experimentation.
Working toward this ultimate goal, Insilico continuously upgrades its Pharma.AI platform by integrating state-of-the-art algorithms, expanding and refining its data sources, and validating its models in real-world case studies. Recently, Insilico announced the final 2025 edition of its Pharma.AI Updates, scheduled for December 10, 2025, from 10:00 to 11:00 a.m. ET. This webinar will provide an in-depth look at major updates across key applications, including PandaOmics, Generative Biologics, Chemistry42, and Science42: DORA, through interactive demos and real-world case studies.
This major upgrade focuses on enhancing scientific rigor, enterprise-grade security, user experience, and a deeper, more mechanistic understanding of biology and chemistry, which is towards Pharmaceutical Superintelligence.
Key Highlights Include:
Generative Biologics applies physics-driven precision to binder design with automated molecular dynamics simulations, advanced scoring function, and interactive contact analysis.
Chemistry42 strengthens its analytical tools lineup with the upcoming features including MolSpace for versatile chemical space exploration and PACE for patent analysis.
PandaOmics for Target and Biomarker Discovery: More secure, more user‑friendly, and scientifically more advanced.
DORA for scientific content drafting: Developed with strong partners to support open‑source code preparation and analysis workflows.
MMAI Gym for Science: Dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10× performance gains on key drug discovery benchmarks
"Every upgrade of Pharma.AI marks a pivotal step in our mission to build a truly end-to-end biological and chemistry intelligence innovation loop," said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. "By being the first in the industry to introduce AI Gym for general-purpose LLMs, delivering advanced modules in Chemistry 42 and rolling out critical enhancements to PandaOmics, Generative Biologics, and DORA, we are providing our partners with an unparalleled ability to navigate complex biological and chemical data, de-risk their programs earlier, and ultimately accelerate the entire discovery process."
Register now to join Insilico's upcoming Pharma.AI Quarterly Launch Webinar: Q4 Winter Edition to get an exclusive look at the latest breakthroughs, game-changing updates, and future-shaping innovations across Pharma.AI.
In 2016, Insilico first described the concept of using generative AI for designing novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since then, Insilico has kept integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning biology, chemistry, medicine development, and science research. Powered by Pharma.AI, Insilico has nominated over 20 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of more than 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated a significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-edge automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across various industries, including advanced materials, agriculture, nutritional products, and veterinary medicine.
For more information, please visit www.insilico.com.
END
Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence
2025-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Study finds most people trust doctors more than AI but see its potential for cancer diagnosis
2025-12-08
FOR IMMEDIATE RELEASE
EMBARGOED UNTIL DECEMBER 8, 2025
Study Finds Most People Trust Doctors More than AI But See Its Potential for Cancer Diagnosis
Nationally representative surveys measure public attitudes toward AI in healthcare
Washington, D.C., December 8, 2025– New research on public attitudes toward AI indicates that most people are reluctant to let ChatGPT and other AI tools diagnose their health condition, but see promise in technologies that use AI to help diagnose cancer. These and other results of two nationally representative surveys will be presented at the ...
School reopening during COVID-19 pandemic associated with improvement in children’s mental health
2025-12-08
Embargoed for release: Monday, December 8, 2025, 4:00 PM ET
Key points:
Children whose schools reopened during the COVID-19 pandemic had significantly decreased mental health diagnoses relative to children whose schools remained closed, according to a new study of schools across California. This included fewer diagnoses of depression, anxiety, and ADHD. Girls’ mental health benefited the most.
Mental health care spending decreased by up to 11% by the ninth month after a school’s reopening.
The study is among the largest and most data-rich examinations of how school closures impacted ...
Research alert: Old molecules show promise for fighting resistant strains of COVID-19 virus
2025-12-08
SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, University of California San Diego scientists and an international team of researchers have identified several promising molecules that could lead to new medications capable of combating these resistant variants.
Instead of looking for antiviral candidates from scratch, the research team screened 141 previously synthesized compounds that had originally been designed between 1997 and 2012 to inhibit a key enzyme called cruzain. ...
Journal of Nuclear Medicine Technology supplement highlights advances in theranostics and opportunities for growth
2025-12-08
Reston, VA (December 8, 2025) As nuclear medicine theranostics expands rapidly across clinical practice worldwide, a new supplement to the Journal of Nuclear Medicine Technology (JNMT) explores how nuclear medicine technologists are embracing their growing role within the field. Titled, Building the Future of Theranostics: Advancing Practice, Education, and Innovation Worldwide, the supplement brings together voices from across the globe, offering perspectives that span clinical lessons, educational frameworks, operational strategies, advocacy, equity, and biology.
From the early use of ...
New paper rocks earthquake science with a clever computational trick
2025-12-08
Hoboken, N.J., December 8, 2025 — On Saturday December 6, 2025 Alaska was rocked by a 7.0 magnitude quake. Though not always so forceful, earthquakes happen every day. On average, about 55 of them strike daily, according to the United States Geological Survey (USGS), totaling some 20,000 annually worldwide. About once a year, one reaches 8.0 points or greater and 15 others hit within the magnitude 7 range on the Richter scale, which measures earthquakes by the energy they release. For example, in just 2025 an 8.8 earthquake offshore from the Kamchatka Peninsula in Russia, ...
ASH 2025: Milder chemo works for rare, aggressive lymphoma
2025-12-08
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 8, 2025, AT 2:45 P.M. EST) – Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Lead researcher Juan Alderuccio, M.D., a hematologist and lymphoma specialist at Sylvester, will present this research Dec. 8 at the American Society of Hematology ...
Olfaction written in bones: New insights into the evolution of the sense of smell in mammals
2025-12-08
The sense of smell is vital for animals, as it helps them find food, protect themselves from predators and interact socially. An international research team led by Dr Quentin Martinez and Dr Eli Amson from State Museum of Natural History Stuttgart has now discovered that certain areas of the brain skull allow conclusions to be drawn about the sense of smell in mammals. Particularly significant is the volume of the endocast of the olfactory bulb, a bony structure in the skull that is often well preserved even in very old fossils. This volume is closely related to the number of intact odour receptor genes – an important ...
Engineering simulations rewrite the timeline of the evolution of hearing in mammals
2025-12-08
One of the most important steps in the evolution of modern mammals was the development of highly sensitive hearing. The middle ear of mammals, with an eardrum and several small bones, allows us to hear a broad range of frequencies and volumes, which was a big help to early, mostly nocturnal mammal ancestors as they tried to survive alongside dinosaurs.
New research by paleontologists from the University of Chicago shows that this modern mode of hearing evolved much earlier than previously thought. Working with detailed CT scans of the skull and jawbones of Thrinaxodon liorhinus, a 250-million-year-old mammal predecessor, they used engineering methods to simulate ...
New research links health impacts related to 'forever chemicals' to billions in economic losses
2025-12-08
The negative health impacts from contamination by so called "forever chemicals" in drinking water costs the contiguous U.S. at least $8 billion a year in social costs, a University of Arizona-led study has found.
The study, published in the Proceedings of the National Academy of Sciences, builds on previous research into how PFAS – per- and polyfluoroalkyl substances – can negatively impact health when the chemicals contaminate drinking water. The research team studied all births in New Hampshire from 2010-2019, focusing on mothers living ...
Unified EEG imaging improves mapping for epilepsy surgery
2025-12-08
A new advance from Carnegie Mellon University researchers could reshape how clinicians identify the brain regions responsible for drug-resistant epilepsy. Surgery can be a life-changing option for millions of epilepsy patients worldwide, but only if physicians can accurately locate the epileptogenic zone, the area where seizures originate.
Bin He, professor of biomedical engineering, and his team have developed a unified, machine learning-based approach called spatial-temporal-spectral imaging (STSI) to assist. It is the first technology capable of analyzing every major type of epileptic ...